1.21
+0.05(+4.31%)
Currency In USD
| Previous Close | 1.16 |
| Open | 1.16 |
| Day High | 1.22 |
| Day Low | 1.11 |
| 52-Week High | 13.5 |
| 52-Week Low | 0.99 |
| Volume | 432,684 |
| Average Volume | 978,959 |
| Market Cap | 61.4M |
| PE | -0.52 |
| EPS | -2.34 |
| Moving Average 50 Days | 1.46 |
| Moving Average 200 Days | 3.24 |
| Change | 0.05 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $121 as of May 09, 2025 at a share price of $1.21. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $157.96 as of May 09, 2025 at a share price of $1.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 26, 2025 1:00 PM GMT
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoim
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
GlobeNewswire Inc.
Feb 18, 2025 3:21 PM GMT
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients di
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
GlobeNewswire Inc.
Feb 18, 2025 12:00 PM GMT
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients di